semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 1.0-120.0,  Breast Cancer Histologically confirmed stage IIB, IIIA, IIIB, IIIC, or previously untreated stage IV primary carcinoma of the breast Fine needle aspiration, core needle biopsy, or incisional biopsy allowed No excisional biopsy Any of the following Tumor size 2, Nodes 1 (T2N1) or tumor size 3 nodes 0 (T3N0) Any T with N2 (including axillary lymph nodes matted to one another) or N3 Any T4, including inflammatory breast cancer Adjuvant patients with at least 4 positive lymph nodes and HER-2 overexpressing tumor Supraclavicular or infraclavicular positive lymph nodes without distant metastases Distant metastases with measurable disease in breast or lymph nodes
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Histologically or "triple diagnosis" (palpation, mammogram or ultrasound, and cytology) confirmed operable invasive breast cancer T0-2, N0 Diagnosis by excisional tumorectomy allowed Clinically occult invasive disease must be histologically confirmed Only 1 tumor in 1 breast Tumor between 5 and 50 mm in largest diameter, within 1 quadrant by mammogram, ultrasound or MRI Multifocal (i.e., within one quadrant and sharing the same histological characteristics) is allowed Multicentric (i.e., in different quadrants) breast cancer is not allowed Clinically negative axillary lymph nodes No metastatic disease
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically or cytologically confirmed metastatic breast cancer with HER2 overexpression Radiographically or physically measurable disease that can be biopsied safely under local anesthesia Hormone receptor status Not specified Age and over Sex Male or female Menopausal status Not specified Performance status ECOG 0-2 Life expectancy Not specified Hematopoietic Neutrophil count at least 1,000/mm^3
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer postmenopausal women metastatic breast cancer suitable for endocrine therapy positive hormone receptor status Human epidermal growth factor receptor 2 (HER2) overexpression  patients on hormone replacement therapy previous chemotherapy for metastatic disease uncontrolled cardiac disease and history of cardiac failure
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-74.0,  Breast Cancer for Breast Cancer and High-Risk Patients Age greater than or equal to 18 years and less than or equal to 74 years Women with a unilateral invasive or noninvasive (DCIS) breast cancer of epithelial origin Women without breast cancer, but with a Gail Index greater than 1.67 percent, or a cumulative lifetime risk greater than or equal to double the age and race-matched general population risk Women known to be BRCA1/2 or other hereditary genes mutation carriers Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal hyperplasia, or LCISl Women may be either premenopausal or postmenopausal. Postmenopausal is defined by the absence of menstrual periods for at least 12 months Postmenopausal women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of greater than 40 IU/ml, and a serum estradiol level of less than 40 pg/ml to document postmenopausal status Breast cancer may be invasive or noninvasive, and in the past or the present  for Breast Cancer Patients Contralateral breast prosthesis Pregnancy History of radiation therapy to the contralateral breast Lactating breasts Chemotherapy within the past 1 month Current antiestrogen therapy Current hormonal replacement therapy or oral contraceptives Concurrent infection Previous contralateral major duct excision
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed breast cancer Stage IV or locally advanced disease Staged by bone scan or CT scan of chest and/or abdomen within the past 6 weeks HER2/neu positive by fluorescent in situ hybridization (if 2+ by immunohistochemistry) or 3+ by immunohistochemistry Measurable disease defined by 1 of the following At least 1 dimension at least 1 cm by CT scan or other imaging scan At least 1 diameter at least 1 cm by plain x-ray (excluding bone lesions) Palpable lesion with both diameters at least 1 cm with caliper OR Evaluable disease defined by 1 of the following Positive bone scan
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Breast Cancer Histologically confirmed breast cancer confined to the breast and axillary nodes No distant metastatic disease Tumor detected in the internal mammary chain by sentinel node procedure allowed Must have undergone 1 of the following procedures for primary breast cancer within the past 12 weeks and have no known clinical residual locoregional disease Total mastectomy with or without adjuvant radiotherapy Breast-conserving surgery (e.g., lumpectomy, quadrantectomy, or partial mastectomy with margins clear* of invasive cancer and ductal carcinoma in situ) followed by radiotherapy NOTE: *If all other margins are clear, a positive posterior (deep) margin is permitted, provided the excision was performed down to the pectoral fascia and all tumor has been removed OR a positive anterior (superficial; abutting skin) margin is allowed provided all tumor was removed Prior axillary lymph node dissection or negative axillary sentinel node biopsy required Patients with microscopically positive axillary sentinel nodes allowed provided they were evaluated on a clinical trial evaluating microscopically positive lymph nodes No locally advanced, inoperable breast cancer, including any of the following characteristics Inflammatory breast cancer
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed stage I-III invasive breast cancer Operable disease Stage I, II, IIIA, and IIIC (T1-3, N3a only) No T4 tumors High-risk disease, defined by 1 of the following Tumor ≥ 2 cm in greatest diameter (includes both invasive and intraductal component) Patients with nodal status of N0+ (i.e., no cluster of tumor cells in any node greater than 0.2 mm) are considered to be node negative and must have a primary tumor ≥ 2 cm in size or have a tumor ≥ 1 cm with high risk features Patients who are node negative on the basis of a sentinel node procedure and fewer than 6 axillary nodes are removed are eligible OR at least 6 axillary or intramammary nodes must be negative Tumor ≥ 1 cm in diameter and meeting 1 of the following ER-negative and PgR-negative
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma Largest tumor lesion ≤ 5 cm Palpable or nonpalpable breast lesion Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions Prior (preoperative) or planned (intraoperative) sentinel node biopsy required At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension No clinical evidence of distant metastases No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI, or CT scan, including the following Skeletal pain of unknown cause Elevated alkaline phosphatase
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Breast Cancer Diagnosis of ductal carcinoma in situ within the past 6 months Locally excised with tumor-free margins at least 1 mm Hormone receptor status Estrogen or progesterone receptor positive Equal to or greater than 5% positive cells Age to 70 Sex Female Menopausal status Postmenopausal, defined as meeting at least 1 of the following Over age 60 Prior bilateral oophorectomy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Neoplasms Female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease) Adequate bone marrow, liver, and renal function  Adjuvant chemotherapy given in the past 12 months Uncontrolled brain metastases
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Histologically or cytologically confirmed breast cancer Locally advanced disease (stage II or III) Not amenable to breast-conserving therapy at the time of diagnosis Measurable disease meeting 1 of the following Bidimensionally measurable palpable lesion at least 1 cm by caliper Unidimensionally measurable lesion at least 1 cm by a positive mammogram, ultrasound, or MRI No evidence of disease outside the breast or chest wall except ipsilateral axillary lymph nodes Hormone receptor status Estrogen and/or progesterone receptor positive Age Postmenopausal Sex
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Patients must be greater than or equal to 18 years of age The patient must have a life expectancy of at least 10 years, excluding her diagnosis of breast cancer. (Comorbid conditions and performance status should be taken into consideration, but not the diagnosis of breast cancer.) The interval between the last surgery for breast cancer treatment (lumpectomy, mastectomy, sentinel lymph node biopsy, axillary surgery, or re-excision of lumpectomy margins) and randomization must be no more than 84 days The tumor must be invasive adenocarcinoma on histologic examination. (Patients with tumors that are pure tubular or mucinous adenocarcinomas are not eligible.) The primary tumor must be T1-3 by clinical and pathologic evaluation Lymph nodes obtained from all axillary staging procedures must be pN0 according to pathologic staging of the 6th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Patients must have undergone axillary nodal staging procedures, for example sentinel node (SN) biopsy alone, SN biopsy followed by axillary sampling or completion dissection, or axillary node dissection to obtain lymph nodes for pathologic evaluation. If the patient has palpable nodes, axillary dissection is required Patients must have an estrogen receptor (ER) analysis performed on the primary tumor prior to randomization. If ER is negative, then progesterone receptor (PgR) analysis must be performed. If ER is positive, PgR analysis is desired, but not mandatory. ("Marginal" or "borderline" results [i.e., those not definitively negative] will be considered positive regardless of the methodology used.) Patients must have had either a lumpectomy or total mastectomy Patients must have no clinical or radiologic evidence of metastatic disease
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer Patients with clinical stage I lung cancer for whom surgical resection is planned are eligible. Histologic confirmation of lung cancer is not required prior to registration or surgical exploration. Preoperative mediatinoscopy is allowed but not required in those patients with indications for mediatinoscopy. It is preferred that that mediatinoscopy be done at a different setting (prior to registration), but the procedure may be done at the same setting as the lobectomy. 2. No prior therapy for this diagnosis. 3. No prior treatment with mediastinal radiation therapy. 4. Age ≥ 18 years of age. 5. ECOG performance status: 0-2
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Glioblastoma Multiforme Anaplastic Astrocytoma Oligoastrocytoma Patients must be ≥18 years old Patients must have undergone a gross total resection of the solid contrast-enhancing lesion(s) > 1.0 cm in diameter Patients must be able to have catheters placed within 14 days of tumor resection (including a planned Gross Total Resection following an initial biopsy or subtotal resection) Patients must have histopathologic confirmation of malignant glioma from resection specimen. Diagnosis must be consistent with either GBM, AA, or malignant mixed OA Patients must be in adequate general condition and meet the following a. Karnofsky Performance Scale score ≥ 70 b. Adequate hematologic status Absolute neutrophil count ≥ 1,500/mm³ Hemoglobin ≥ 10 gm/dL Platelets ≥ 100,000/mm³  Patients with residual contrast-enhancing tumor crossing the midline, multifocal tumor not amenable to gross total resection or non-parenchymal tumor dissemination (e.g., subependymal or leptomeningeal) Patients with clinically significant increased ICP (e.g., impending herniation), uncontrolled seizures or requirement for immediate palliative treatment Patients who have received any prior anti-tumor treatment (other than corticosteroids) including any investigational agents Patients with any metallic prosthesis that would prevent MRI and/or MRS scanning procedures of the brain Patients unwilling or unable to follow protocol requirements
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Breast Cancer Diagnosis of invasive breast cancer Tumor ≥ 3 cm and palpable Multiple masses are allowed provided at least 1 mass is ≥ 3 cm Clinically positive axillary or supraclavicular lymph nodes allowed Fine needle aspiration or core needle biopsy positive for invasive breast cancer AND/OR fine needle aspiration of lymph nodes positive HER2/neu-positive OR negative No inflammatory breast cancer No distant metastases Hormone receptor status Estrogen receptor (ER)-positive OR ER-negative Age